Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.
Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.
复制标题
延长胃肠道间质瘤无瘤寿命，术前伊马替尼干预的最佳建议
DOI：
10.7150/jca.25263
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Tang WZ
中科院分区：
文献类型：
--
作者：
Yan LH;Chen ZN;Li CJ;Chen J;Qin YZ;Chen JS;Tang WZ
背景：伊马替尼被认为是第一个成功合成的靶向阻断酪氨酸激酶的小分子。其高疗效使80%以上的慢性髓性白血病（CML）患者的生存期超过10年。由于胃肠道间质瘤（GIST）的癌变与CML相似，伊马替尼已被批准用于一线治疗。研究设计：我们的回顾性研究拟纳入191例肿瘤较大（≥8cm）且术前接受伊马替尼的直接手术GIST患者。分析包括人口统计学、癌症特异性生存率及其危险因素的关系。结果：男性患者和胃肠道部位占总病例的比例较高，KIT突变体检测占所有可追溯基因检测的89.7%。术前使用伊马替尼的患者在1年和3年后的癌症特异性生存（CSS）均高于对照组。肿瘤大小超过其阈值8cm将是预后不良的危险因素。结论：综上所述，对于高危患者，术前应考虑使用伊马替尼，以减缓肿瘤进展，创造手术机会，但该干预的确切持续时间有待进一步验证。
Background: Imatinib has been regarded as the first successful synthetic small molecule targeting at blocking tyrosine kinase. Its high efficacy stabilized disease in above 80% of chronic myeloid leukemia (CML) patients over 10 years survival. Due to the similar canceration of gastrointestinal stromal tumor (GIST) as to CML, imatinib has been approved to be used as first-line treatment. Study design: Our retrospective study was proposed to enroll 191 GIST patients with larger tumor size (≥8 cm) who preoperative accepted imatinib from those with direct operation. Analysis included demographics, cancer specific survival and relationship of their risk factors. Results: Male patients and gastrointestinal (GI) tract location took higher proportion in total cases, detection of KIT mutant took 89.7% among all traceable genetic testing. Patients with preoperative imatinib can achieve higher cancer specific survival (CSS) after both in 1 year and 3 years duration than their counterpart. Tumor size above its threshold of 8 cm would be a hazardous factor for poor prognosis. Conclusion: In conclusion, as for regressing tumor progression and creating operative chance, preoperative imatinib should be considered for the patients with high risk, although the precise duration of this intervention needs further validation.
登录
查看更多内容
DOI：
10.1056/nejmoa1609324
发表时间：
2017-03-09
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hochhaus A;Larson RA;Guilhot F;Radich JP;Branford S;Hughes TP;Baccarani M;Deininger MW;Cervantes F;Fujihara S;Ortmann CE;Menssen HD;Kantarjian H;O'Brien SG;Druker BJ;IRIS Investigators
通讯作者：
IRIS Investigators
影响因子：
50.5
作者：
Mussi, C.;Ronellenfitsch, U.;Gronchi, A.
通讯作者：
Gronchi, A.
影响因子：
45.3
作者：
Joensuu, Heikki;Eriksson, Mikael;Reichardt, Peter
通讯作者：
Reichardt, Peter
影响因子：
37.8
作者：
Aman, Jurjan;van Bezu, Jan;Amerongen, Geerten P. van Nieuw
通讯作者：
Amerongen, Geerten P. van Nieuw
DOI：
10.1158/1055-9965.epi-14-1002
发表时间：
2015-01
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Ma GL;Murphy JD;Martinez ME;Sicklick JK
通讯作者：
Sicklick JK